Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

275 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparison of therapeutic features and oncologic outcome in patients with pN1 prostate cancer among robot-assisted, laparoscopic, or open radical prostatectomy.
Kirisawa T, Shiota M, Kimura T, Edamura K, Miyake M, Morizane S, Yoshino T, Matsukawa A, Matsumoto R, Kasahara T, Nishiyama N, Eto M, Kitamura H, Nakamura E, Matsui Y; Japanese Urological Oncology Group. Kirisawa T, et al. Among authors: matsukawa a. Int J Clin Oncol. 2023 Feb;28(2):306-313. doi: 10.1007/s10147-022-02278-7. Epub 2022 Dec 17. Int J Clin Oncol. 2023. PMID: 36527579
Percutaneous cryoablation versus partial nephrectomy for cT1b renal tumors: An inverse probability weight analysis.
Aikawa K, Yanagisawa T, Fukuokaya W, Shimizu K, Miyajima K, Nakazono M, Iwatani K, Matsukawa A, Obayashi K, Kimura S, Tsuzuki S, Sasaki H, Abe H, Sadaoka S, Miki J, Kimura T. Aikawa K, et al. Among authors: matsukawa a. Urol Oncol. 2023 Mar;41(3):150.e11-150.e19. doi: 10.1016/j.urolonc.2022.11.025. Epub 2023 Jan 4. Urol Oncol. 2023. PMID: 36604229
Docetaxel versus abiraterone for metastatic hormone-sensitive prostate cancer with focus on efficacy of sequential therapy.
Yanagisawa T, Hata K, Narita S, Hatakeyama S, Mori K, Yata Y, Sano T, Otsuka T, Hara S, Miyajima K, Enei Y, Fukuokaya W, Nakazono M, Matsukawa A, Miki J, Habuchi T, Ohyama C, Shariat SF, Kimura T. Yanagisawa T, et al. Among authors: matsukawa a. Prostate. 2023 May;83(6):563-571. doi: 10.1002/pros.24488. Epub 2023 Jan 20. Prostate. 2023. PMID: 36661102
En Bloc Resection Versus Conventional TURBT for T1HG Bladder Cancer: A Propensity Score-Matched Analysis.
Yanagisawa T, Matsukawa A, Iwatani K, Sato S, Hayashida Y, Okada Y, Yorozu T, Fukuokaya W, Sakanaka K, Urabe F, Kimura S, Tsuzuki S, Shimoda M, Takahashi H, Miki J, Shariat SF, Kimura T. Yanagisawa T, et al. Among authors: matsukawa a. Ann Surg Oncol. 2023 Jun;30(6):3820-3828. doi: 10.1245/s10434-023-13227-7. Epub 2023 Mar 10. Ann Surg Oncol. 2023. PMID: 36897417
ASO Author Reflections: Is T1HG Bladder Cancer a Good Candidate for En Bloc Resection?
Yanagisawa T, Miki J, Matsukawa A, Iwatani K, Sato S, Hayashida Y, Okada Y, Shimoda M, Takahashi H, Shariat SF, Kimura T. Yanagisawa T, et al. Among authors: matsukawa a. Ann Surg Oncol. 2023 Jun;30(6):3829-3830. doi: 10.1245/s10434-023-13291-z. Epub 2023 Mar 12. Ann Surg Oncol. 2023. PMID: 36907962 No abstract available.
[No title available]
[No authors listed] [No authors listed] PMID: 37040049
Clinical impact of detrusor muscle in en bloc resection for T1 bladder cancer.
Yanagisawa T, Sato S, Hayashida Y, Okada Y, Fukuokaya W, Iwatani K, Matsukawa A, Shimoda M, Takahashi H, Kimura T, Shariat SF, Miki J. Yanagisawa T, et al. Among authors: matsukawa a. Urol Oncol. 2023 Dec;41(12):484.e7-484.e15. doi: 10.1016/j.urolonc.2023.08.004. Epub 2023 Sep 14. Urol Oncol. 2023. PMID: 37714725
275 results